Detalles de la búsqueda
1.
SDG 14.5: at last, a breakthrough for the 2030 agenda.
Nature
; 621(7978): 258, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37700043
2.
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
Support Care Cancer
; 25(1): 85-92, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27557833
3.
Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
Cancer
; 122(15): 2418-25, 2016 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27176138
4.
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
Lancet Oncol
; 16(9): 1071-1078, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26272768
5.
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
Lancet Oncol
; 16(9): 1079-1089, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26272769
6.
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Support Care Cancer
; 23(11): 3281-8, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25940030
7.
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Arthritis Rheumatol
; 75(12): 2185-2194, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37459248
8.
Pharmacokinetics, Safety, and Tolerability of Rolapitant Administered Intravenously Following Single Ascending and Multiple Ascending Doses in Healthy Subjects.
Clin Pharmacol Drug Dev
; 8(2): 160-171, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29905976
9.
Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.
J Clin Pharmacol
; 59(4): 488-499, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30422319
10.
An Open-Label, Randomized, Pivotal Bioequivalence Study of Oral Rolapitant.
Clin Pharmacol Drug Dev
; 8(2): 152-159, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30624856
11.
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
JAMA Oncol
; 5(8): 1132-1140, 2019 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31194225
12.
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
J Clin Oncol
; 37(32): 2968-2973, 2019 11 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31173551
13.
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
JAMA Oncol
; 5(8): 1141-1149, 2019 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31194228
14.
Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment.
J Clin Pharmacol
; 58(5): 686-693, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29329482
15.
Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy.
Cancer Med
; 7(7): 2943-2950, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29790666
16.
Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.
J Clin Pharmacol
; 58(2): 202-211, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28906558
17.
Effects of Rolapitant Administered Intravenously on the Pharmacokinetics of a Modified Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan) in Healthy Subjects.
J Clin Pharmacol
; 58(8): 1074-1083, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29693712
18.
Bioequivalence of Intravenous and Oral Rolapitant: Results From a Randomized, Open-Label Pivotal Study.
J Clin Pharmacol
; 57(12): 1600-1606, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28906561
19.
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Eur J Cancer
; 57: 23-30, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26851398
20.
Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study.
Clin Infect Dis
; 41(6): 808-14, 2005 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16107978